Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
3378.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.86B
Close$
$20.57
28.6% downside
Current Fair Value
28.6% downsideOvervalued by 28.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.86 Billion |
|---|---|
| Enterprise Value | $14.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.28 |
| Beta | -1.14 |
| Outstanding Shares | 2,726,200,000 |
Return
| Return on Equity | 10.61% |
|---|---|
| Return on Assets | 2.27% |
| Return on Invested Capital | 5.56% |
Valuation & Multiples
| P/E Ratio | 87.62 |
|---|---|
| PEG | 424.74 |
| Price to Sales | 5.76 |
| Price to Book Ratio | 9.61 |
| Enterprise Value to Revenue | 1.06 |
| Enterprise Value to EBIT | 15.04 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | 2.35 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
60 employees
CEO: Qixiang Li Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical tr...